| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of 1 Surgery, 2 Internal Medicine, Division of Cardiovascular Diseases, and 3 Physiology and Biophysics, Mayo Clinic and Foundation, Rochester, Minnesota 55905
In experimental hypercholesterolemia, endothelium-dependent relaxations decrease, as does endothelial immunoreactivity for nitric oxide (NO) synthase (NOS; eNOS) in coronary arteries. Systemic levels of NO also decrease with concomitant elevations in systemic circulating levels of endothelin (ET)-1. Chronic treatment of hypercholesterolemic pigs with ET-receptor antagonists increases circulating NO and improves endothelium-dependent relaxations. Mechanisms causing these increases are not known. Therefore, experiments were designed to test the hypothesis that chronic administration of ET-receptor antagonists to hypercholesterolemic pigs increases NO production through increases in NOS activity. Female juvenile pigs were fed a 2% cholesterol atherogenic diet and were randomly allocated to receive no treatment (controls), a selective ETA-receptor antagonist (ABT-624), or a combined ETA + ETB-receptor antagonist (RO-48-5695) daily for 12 wk. After 12 wk, endothelial cells from thoracic aorta were prepared for measurement of eNOS mRNA or eNOS activity. Total cholesterol, low-density-lipoprotein cholesterol, and concentrations of ET-1 were significantly higher in all three groups at 12 wk compared with baseline levels. Circulating plasma-oxidized products of NO (NOx) increased with ET-receptor blockade. NOS mRNA was similar among groups. Total and Ca-dependent NOS activity was significantly higher in aortic endothelial cells from the ETA + ETB-treated pigs compared with those treated with ETA antagonist alone. These results suggest that changes in systemic NOx after chronic inhibition of ETA + ETB receptors in hypercholesterolemia may result from posttranscriptional changes in NOS.
atherosclerosis; endothelial cells; endothelin-1; lipidemia; messenger ribonucleic acid
This article has been cited by other articles:
|
|
 |
|
  F. Bohm and J. Pernow The importance of endothelin-1 for vascular dysfunction in cardiovascular disease Cardiovasc Res, October 1, 2007; 76(1): 8 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Girgis, H. C. Champion, G. B. Diette, R. A. Johns, S. Permutt, and J. T. Sylvester Decreased Exhaled Nitric Oxide in Pulmonary Arterial Hypertension: Response to Bosentan Therapy Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 352 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Sosin, G. S. Bhatia, R. C. Davis, and G. Y.H. Lip Heart failure--the importance of ethnicity Eur J Heart Fail, December 1, 2004; 6(7): 831 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Mather, A. Lteif, H. O. Steinberg, and A. D. Baron Interactions Between Endothelin and Nitric Oxide in the Regulation of Vascular Tone in Obesity and Diabetes Diabetes, August 1, 2004; 53(8): 2060 - 2066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Thirunavukkarasu, Y Yang, V M Subbotin, S A K Harvey, J Fung, and C R Gandhi Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats Gut, July 1, 2004; 53(7): 1010 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Gonon, D. Erbas, A. Broijersen, G. Valen, and J. Pernow Nitric oxide mediates protective effect of endothelin receptor antagonism during myocardial ischemia and reperfusion Am J Physiol Heart Circ Physiol, May 1, 2004; 286(5): H1767 - H1774. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
